Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized discontinuation study of GW786034 in clear-cell renal cell carcinoma
2005-002212-13Phase 2Terminated
- Sponsor
- GSK
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in renal cell carcinoma (RCC) comparing GW786034 continuation arm with Placebo arm (2 arms). Primary endpoints: Progressive disease rate at 16 weeks post-randomization and Stable disease rate at 12 weeks in lead-in phase. Started Aug 2005; status: terminated.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2005-002212-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002212-13.